Research Paper Volume 11, Issue 7 pp 2138—2150
MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway
Figure 4. Role of the miR-204/CAV-1 axis in regulating cisplatin sensitivity in NSCLC. (A) Effect of miR-204 (50 pmol/ml) on the sensitivity of CR-A549 cells to cisplatin treatment (0–60 μM). *P<0.05 vs. NCO group. (B) Effect of miR-204 (50 pmol/ml) on the sensitivity of CR-PC9 cells to cisplatin treatment (0–60 μM). *P<0.05 vs. NCO group. (C) Effect of the CAV-1 plasmid (2 μg/ml) on protecting the CR-A549 and CR-PC9 cells that were co-treated with cisplatin (8 μM) and miR-204 (50 pmol/ml). *P<0.05 vs. Cisplatin+NCO group. #P<0.05 vs. Cisplatin+miR-204 group. (D) Effect of the anti-miR-204 (50 pmol/ml) on protecting the A549 and PC9 cells that were co-treated with cisplatin (8 μM). *P<0.05 vs. Cisplatin+NCO group.